Treatment Response Biomarkers in MDD

Официальное название

Prospective Biomarkers for Treatment Response in Major Depressive Disorder

Обзор

This experiment intends to explore the differences among various types of depression, as well as the differences between healthy subjects and depressed patients, and find possible biological markers from the severity of symptoms, social function and cognitive function of depressed patients, combined with EEG characteristics, biological test indicators (blood, faeces, hair, etc.) and functional magnetic resonance imaging data. To explore the changes in clinical symptoms, cognitive and social functions, and biological indicators of various types of patients before and after treatment, to provide references for the prognosis of various types, and to predict the future development of the disease according to the baseline indicators of patients; According to the above aspects, this experiment can follow up the patients with depression, track their disease development, and study the potential biological changes in the early stage of the disease, which has the potential to reveal the pathogenesis and provide guidance for the early diagnosis and intervention of depression.

Подробное описание

More specifically, the goals of this study are to 1) explore the potential biomarkers for Major Depressive Disorder by comparing MDD patients and healthy controls; 2) investigate the biochemical indicators for subtypes of MDD through long-term cohort follow-up studies; 3) investigate the differences and similarities among different types of MDD patients in terms of cognitive functions, biological tests, as well as neuroimaging data; 4) evaluate and analyze the prognosis of patients according to the baseline level, and search for the biomarkers regarding MDD treatment response to guide the clinical treatment and intervention of patients with MDD; 5) Through the long-term follow-up study, the behavioural and biochemical indicators of the patients with MDD were collected, the differences between the indicators before and after remission were examined, and the state and quality of the pathophysiological indicators of the patients with MDD were investigated.

Первичные конечные точки

• Change in Hamilton Depression Rating Scale-24 item (HAMD-24)Interview-based questionnaire used to measure the severity of depression [Срок оценки: 8weeks]

Вторичные конечные точки (5)

• Change in Hamilton Depression Rating Scale-17 item (HAMD-17)Interview-based questionnaire used to measure the severity of depression. [Срок оценки: Baseline, 2weeks, 1 month, 2 months，4months，6months，1year]
• Change in Hamilton Anxiety Rating Scale-14 item (HAMA-14)Interview-based questionnaire used to measure the severity of anxiety. [Срок оценки: Baseline, 2weeks, 1 month, 2 months，4months，6months，1year]
• Change in DSST (Number of Correct Symbols) [Срок оценки: Baseline, 2weeks, 1 month, 2 months，4months，6months，1year]
• Change in Generalized Anxiety Disorder-7 (GAD-7) [Срок оценки: Baseline, 2weeks, 1 month, 2 months，4months，6months，1year]
• Change in Patient Health Questionnaire-9 (PHQ-9) [Срок оценки: Baseline, 2weeks, 1 month, 2 months，4months，6months，1year]

Критерии участия

Критерии включения

• The subject is an outpatient/inpatient (but the subject who participated in the experimental treatment does not need to be hospitalized), and passed M.I.N.I. interview confirmed that the subjects met DSM-5 diagnostic criteria of current or past major depressive disorder.
• Age 18-60 years old, regardless of gender;
• Right-handed;
• Junior high school education or above, capable of completing informed consent and cognitive test;
• During the follow-up period, the subjects can take antidepressant treatment according to the doctor's advice of outpatient or resident.

\-

Критерии исключения

• Patients with psychotic symptoms;
• M.I.N.I. was diagnosed as schizophrenia, schizophrenic affective disorder, schizophrenia-like disorder, Paranoia or current mental symptoms, post-traumatic stress disorder (currently or within the past year) or dysthymia;
• with brain organic and serious physical diseases (such as thyroid disease, lupus erythematosus, diabetes, lung, liver and kidney) damage, infection, major trauma, etc.) exclude intracranial implants;
• Clinically significant sensory disturbance that can't be corrected (for example, hearing impairment makes conversation impossible);
• Pregnant and lactating women; -

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения

Другое

Центры проведения

Китай · 1 центр

• Central South University — Чанша

Идентификаторы

NCT: NCT05585047 · MDD202011

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗